mutations and sophisticated kar yotype. It follows a linear evolution in the CLL clone with the recurrent acquisition of CDKN2A Genetic susceptibility mechanisms. Most susceptibility loci map to non-coding locations on the genome, are primarily situated in active promoters or enhancers, and modif